Stock market today: S&P 500 drops for fifth day as focus shifts to Powell’s speech
BOSTON—Jonathan Anderman, General Counsel and Corporate Secretary at Compass Therapeutics, Inc. (NASDAQ:CMPX), recently acquired a significant number of shares in the company. According to a recent SEC filing, Anderman purchased 20,000 shares of common stock on April 7, 2025, at a price of $1.54 per share. This transaction totaled approximately $30,800. The purchase comes as the stock has fallen nearly 30% in the past week, according to InvestingPro data.
Following this transaction, Anderman's total direct ownership of Compass Therapeutics stock increased to 21,000 shares. This acquisition reflects Anderman's continued investment in the company's future. Compass Therapeutics, based in Boston, is a biotechnology firm focused on developing innovative therapies. While the company maintains a strong cash position with more cash than debt and a healthy current ratio of 14.96x, InvestingPro analysis indicates rapid cash burn. Analyst price targets range from $6 to $32, suggesting significant potential upside from current levels. Get access to 8 more exclusive InvestingPro Tips and comprehensive insider trading analysis with an InvestingPro subscription.
In other recent news, Compass Therapeutics announced positive results from its COMPANION-002 Phase 2/3 trial, which evaluated tovecimig combined with paclitaxel for advanced biliary tract cancer. The combination therapy showed a statistically significant improvement in overall response rate compared to paclitaxel alone, with a notable increase in response rates. Additionally, Leerink Partners upgraded Compass Therapeutics' stock rating from Market Perform to Outperform, raising the price target from $4 to $6, due to a positive outlook on the company's clinical programs. Piper Sandler also initiated coverage on Compass Therapeutics with an Overweight rating and a $12 price target, reflecting confidence in the company's prospects. Meanwhile, Stifel maintained a Buy rating with a $10 price target, emphasizing the importance of upcoming trial data as a significant milestone. Compass Therapeutics reported progress on its clinical development programs, including the advancement of CTX-10726 and the full enrollment of a dosing cohort in the CTX-8371 Phase 1 study. The company ended 2024 with an estimated $127 million in cash and marketable securities, expected to fund operations into early 2027. These developments highlight the company's ongoing efforts and potential future milestones in oncology treatments.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.